Nontuberculous mycobacteria in the HIV infected patient.
The reduction in disseminated NTM infections caused by HAART is one of the success stories in the history of HIV in the developed world. Despite this success, these diseases still occur and may have atypical presentations in patients receiving HAART. Clinicians treating HIV-infected patients must remain familiar with the diagnosis and treatment of these diseases and implement prevention strategies when indicated.
Jones
Denis
D
School of Medicine, University of California, Mail Code 8208, 150 W. Washington Street, #100, San Diego, CA 92103, USA. djones@ucsd.edu
Havlir
Diane V
DV
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015497:HIV-1; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D009170:Nontuberculous Mycobacteria / Q000302:isolation & purification*; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000995:Antitubercular Agents